Cdk2/cdc2 expression in colon carcinogenesis and effects of cdk2/cdc2 inhibitor in colon cancer cells

International Journal of Oncology

Volumn 13, Issue 2, 1998, Pages 233-239

  Yamamoto, H ^a,b   Monden, T ^a   Miyoshi, H ^a   Izawa, H ^a   Ikeda, K ^a   Tsujie, M ^a   Ohnishi, T ^a   Sekimoto, M ^a   Tomita, N ^a   Monden, M ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b College of Physicians and Surgeons ^*  (United States)

Author keywords

Apoptosis; Butyrolactone I; cdc2; cdk2; Colon cancer

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 2 INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CELL PROLIFERATION; COLON ADENOMA; COLON CANCER; COLON CARCINOGENESIS; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0031847296     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.13.2.233     Document Type: Article

References (43)

1. Sherr CJ: Mammalian G1 cyclins. Cell 79: 551-555, 1994.
2. Hunter T and Pines J: Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell 79: 573-582, 1994.
3. Dunphy WG, Brizuela L, Beach D and Newport J: The Xenopus CDC2 protein is a component of MPF, a cytoplasmic regulation of mitosis. Cell 54: 423-431, 1988.
4. Tsai LH, Lees E, Faha B, Harlow E and Riabowol K: The CDK2 kinase is required for the G1-to-S transition in mammalian cells. Oncogene 8: 1593-1602, 1993.
5. Goodrich DW, Wang NP, Qian YW, Lee EY and Lee WH: The retinoblastoma gene product regulates progression through the G1 phase of the cell cycle. Cell 67: 293-302, 1991.
6. Hiebert SW, Chellappan SP, Horowitz JM and Nevins JR: The interaction of RB with E2F coincides with an inhibition of the transcriptional activity of E2F. Genes Dev 6: 177-185, 1992.
7. Akiyama T, Ohuchi T, Sumida S, Matsumoto K and Toyoshima K: Phosphorylation of the retinoblastoma protein by CDK2. Proc Natl Acad Sci USA 89: 7900-7904, 1992.
8. Hinds PW, Mittnacht S, Dulic V, Arnold A, Reed SI and Weinberg RA: Regulation of rctinoblastoma protein functions by ectopic expression of human cyclins. Cell 70: 993-1006, 1992.
9. Kato J, Matsushime H, Hiebert SW, Ewen ME and Sherr CJ: Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D dependent kinase CDK4. Genes Dev 7: 331-342, 1993.
10. Lin BT, Gruenwald S, Morla AO, Lee WH and Wang JYJ: Retinoblastoma carcinoma suppressor gene product is a substrate of the cell cycle regulator CDC2 kinase. EMBO J 10: 857-864, 1991.
11. Harbour JW, Lai SL, Whang-Peng J, Gazdar AF, Minna JD and Kaye FJ: Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science 241: 353-357, 1988.
12. Horowitz JM, Yandell DW, Park SH, Canning S, Whyte P, Buchkovich K, Harlow E, Weinberg RA and Dryja TP: Point mutational inactivation of the retinoblastoma antioncogene. Science 243: 937-940, 1989.
13. Lee EY, To H, Shew JY, Bookstein R, Scully P and Lee WH: Inactivation of the retinoblastoma susceptibility gene in human breast carcinomas. Science 241: 218-221, 1988.
14. Weinberg RA: The retinoblastoma protein and cell cycle control. Cell 81: 323-330, 1995.
15. Keyomarsi K, O'Leary N, Molnar G, Lees E, Fingert HJ and Pardee AB: Cyclin E, a potential prognostic marker for breast carcinoma. Cancer Res 54: 380-385, 1994.
16. Jiang W, Kahan S, Tomita N, Zhang Y, Lu S and Weinstein B: Amplification and expression of the human cyclin D gene in esophageal carcinoma. Cancer Res 52: 2980-2983, 1992.
17. Gillett C, Fantl V, Smith R, Fisher C, Bartek J, Dickson C, Barnes D and Peters G: Amplification and overexpression of cyclin D1 in breast carcinoma detected by immunohistochemical staining. Cancer Res 54: 1812-1817, 1994.
18. Zhang YJ, Jiang W, Chen CJ, Lee CS, Kahn SM, Santella RM and Weinstein IB: Amplification and overexpression of cyclin D1 in human hepatocellular carcinoma. Biochem Biophys Res Commun 196: 1010-1016, 1993.
19. Arber N, Hibshoosh H, Moss SF, Sutter T, Zhang Y, Begg M, Wang S, Weinstein IB and Holt PR: Increased expression of cyclin D1 is an early event in multistage colorectal carcinogenesis. Gastroenterology 110: 669-674, 1996.
20. Bartkova J, Lukas J, Strauss M and Bartek J: The PRAD-1 cyclin D1 oncogene product accumulates aberrantly in a subset of colorectal carcinomas. Int J Cancer 58: 568-573, 1994.
21. Schmidt EE, Ichimura K, Reifenberger G and Collins VP: CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastoma. Cancer Res 54: 6321-6324, 1994.
22. Khatib ZA, Matsushime H, Valentine M, Shapiro DN, Sherr CJ and Look AT: Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas. Cancer Res 53: 5535-5541, 1993.
23. Yasui W, Ayhan A, Kitadai Y, Nishimura K, Yokozaki H, Ito H and Tahara E: Increased expression of p34CDC2 and its kinase activity in human gastric and colonie carcinomas. Int J Cancer 53: 36-41, 1993.
24. Yamamoto H, Monden T, Ikeda K, Izawa U, Fukuda K, Fukunaga M, Tomita N, Shimano T, Shiozaki H and Monden M: Coexpression of cdk2/cdc2 and retinoblastoma gene products in colorectal cancer. Br J Cancer 71: 1231-1236, 1995.
25. Cope R, Christensen MA, Thorson A, Lynch HT, Smyrk T, Hodgson C, Wildrick DM, Cope ML and Boman BM: Increased expression of the retinoblastoma gene in human colorectal carcinomas relative to normal colonie mucosa. J Natl Cancer Inst 82: 310-314, 1990.
26. Gope R and Gope ML: Abundance and state of phosphorylation of the retinoblastoma susceptibility gene product in human colon carcinoma. Mol Cell Biochcm 110: 123-133, 1992.
27. Lothe RA, Fossli T, Danielsen HE, Stenwig AE, Nesland JM, Gallie B and Børresen AL: Molecular genetic studies of tumor suppressor gene regions on chromosomes 13 and 17 in colorectal tumors. J Natl Cancer Inst 84: 1100-1108, 1992.
28. Meling GI, Lothe RA, Børresen AL, Hauge S, Graue C, Clausen OPF and Rognum TO: Genetic alterations within the retinoblastoma locus in colorectal carcinomas. Relation to DNA ploidy pattern studied by flow cytometric analysis. Br J Cancer 64: 475-480, 1991.
29. Kitagawa M, Okabe T, Ogino H, Matsumoto H, Suzuki-Takahashi I, Kokubo T, Higashi H, Saitou S, Taya Y, Yasuda H, Ohba Y, Nishimura S, Tanaka N and Okuyama A: Butyrolactone I, a selective inhibitor of cdk2 and cdc2 kinase. Oncogene 8: 2425-2432, 1993.
30. Kitagawa M, Higashi H, Suzuki-Takahashi I, Okabe T, Ogino H, Taya Y, Nishimura S and Okuyama A: A cyclin-dependent kinase inhibitor, butyrolactone I, inhibits phosphorylation of RB protein and cell cycle progression. Oncogene 9: 2549-2557, 1994.
31. Kawasaki Y, Monden T, Morimoto H, Murotani M, Miyoshi Y, Kobayashi T, Shimano T and Mori T: Immunohistochemical study of p53 expression in microwave-fixed, paraffin-embedded sections of colorectal carcinoma and adenoma. Am J Clin Pathol 97: 244-249, 1992.
32. Liu SQ, Saijo K, Todoroki T and Ohno T: Induction of human autologus cytotoxic T lymphocytes on formalin-fixed and paraffin-embedded tumour sections. Nat Med 1: 267-273, 1995.
33. Fan G, Ma X, Kren BT and Steer CJ: The retinoblastoma gene product inhibits TGF-ß1 induced apoptosis in primary rat hepatocytes and human HuH-7 hepatoma cells. Oncogene 12: 1909-1919, 1996.
34. Craig C, Wcrsto R, Kim M, Ohri E, Li Z, Kalayose D, Lee SJ, Trepel J, Cowan K and Seth P: A recombinant adenovirus expressing p27Kipl induces cell cycle arrest and loss of cyclin-cdk activity in human breast cancer cells. Oncogene 14: 2283-2289, 1997.
35. Spillare EA, Okamoto A, Hagiwara K, Demetrick DJ, Serrano M, Beach D and Harris CC: Suppression of growth in vitro and tumorigcnecity in vivo of human carcinoma cell lines by transfected p16INK4. Mol Carcinog 16: 53-60, 1996.
36. Gotoh A, Kao CH, Ko SC, Hamada K, Liu TJ and Chung LWK: Cytotoxic effects of recombinant adenovirus p53 and cell cycle regulator genes p21 and p16 in human prostate cancers. J Urol 158: 636-641, 1997.
37. Yang ZY, Perkins ND, Ohno T, Nabel EG and Nabel GJ: The p21 cyclin-dependent kinase inhibitor suppresses tumorigenicity in vivo. Nat Med 1: 1052-1056, 1995.
38. Hsiao M, Tse V, Carmel J, Costanzi E, Strauss B, Haas M and Silverberg GD: Functional expression of human p21WAF1/CIP1 gene in rat glioma cells suppresses tumor growth in vivo and induces radiosensitivity. Biochem Biophys Res Commun 233: 329-335, 1997.
39. Chen J, Willingham T, Shuford M and Nisen PD: Tumor suppression and inhibition of anuploid cell accumulation in human brain tumor cells by ectopic overexpression of the cyclin-dependent kinase inhibitor p27KIP1. J Clin Invest 97: 1983-1988, 1996.
40. Yokoyama Y, Takahashi Y, Morishita S, Hashimoto M and Tamaya T: Introduction of p21Waf1/Cip1 gene into a carcinoma cell line of the uterine cervix with inactivated p53. Cancer Lett 116: 233-239, 1999.
41. Arber N, Doki Y, Han EK-H, Sgambato A, Zhou P, Kim N, Delohery T, Klein MG, Holt PR and Weinstein IB: Antisense to cyclin D1 inhibits the growth and tumorigenicity of human colon cancer cells. Cancer Res 57: 1569-1574, 1997.
42. Zhou P, Jiang W, Zhang YJ, Kahn SM, Schieren I, Santella RM and Weinstein IB: Antisense to cycin D1 inhibits growth and reverses the transformed phenotype of human esophageal cancer cells. Oncogene 11: 571-580, 1995.
43. Shibata Y, Nishimura S, Okuyama A and Nakamura T: p53-independent induction of apoptosis by cyclin-depcndcnt kinase inhibition. Cell Growth Differ 7: 887-891, 1996.